Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 92840H400 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
TCG Crossover GP II, LLC
13G/A
|
10.0% |
5/15/2026
Event 3/31/2026
|
||
| TCG Crossover GP I, LLC | 2.6% | |||
| TCG Crossover Fund I, L.P. | 2.6% | |||
| TCG Crossover GP II, LLC | 7.6% | |||
| TCG Crossover Fund II, L.P. | 7.6% | |||
| Chen Yu | 10.0% | |||
|
Biotechnology Value Fund L P
13G/A
|
10.0% |
2/14/2025
Event 12/31/2024
|
||
| Biotechnology Value Fund L P | 5.4% | |||
| BVF I GP LLC | 5.4% | |||
| Biotechnology Value Fund II LP | 4.4% | |||
| BVF II GP LLC | 4.4% | |||
| Biotechnology Value Trading Fund OS LP | 0.6% | |||
| BVF Partners OS Ltd. | 0.6% | |||
| BVF GP Holdings LLC | 9.4% | |||
| BVF Partners L P/IL | 10.0% | |||
| BVF Inc/IL | 10.0% | |||
| Lampert Mark N | 10.0% | |||
|
Commodore Capital LP
13G/A
|
9.9% |
8/14/2026
Event 6/30/2026
|
||
| Commodore Capital LP | 9.9% | |||
| Commodore Capital Master LP | 9.9% | |||
| Robert Egen Atkinson | 9.9% | |||
| Michael Kramarz | 9.9% | |||
|
TCG Crossover GP I, LLC
13G/A
|
6.7% |
8/14/2026
Event 6/30/2026
|
||
| TCG Crossover GP I, LLC | 1.8% | |||
| TCG Crossover Fund I, L.P. | 1.8% | |||
| TCG Crossover GP II, LLC | 5.1% | |||
| TCG Crossover Fund II, L.P. | 5.1% | |||
| Chen Yu | 6.7% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (6) | ||||
|
Great Point Partners, LLC
13G/A
|
4.95% |
2/17/2026
Event 12/31/2025
|
||
| Great Point Partners, LLC | 4.95% | |||
| Dr. Jeffrey R. Jay, M.D. | 4.95% | |||
| Ms. Lillian Nordahl | 4.95% | |||
|
Nantahala Capital Management, LLC
13G/A
|
4.7% |
2/13/2026
Event 12/31/2025
|
||
| Nantahala Capital Management, LLC | 4.7% | |||
| Wilmot B. Harkey | 4.7% | |||
| Daniel Mack | 4.7% | |||
| Vanguard Group Inc 13G/A | 4.6% |
1/30/2026
Event 12/31/2025
|
||
|
StemPoint Capital LP
13G/A
|
1.5% |
2/17/2026
Event 12/31/2025
|
||
| StemPoint Capital LP | 1.5% | |||
| StemPoint Capital Management GP LLC | 1.5% | |||
| Michelle Ross | 1.5% | |||
| Janus Henderson Group PLC 13G/A | 0% |
2/17/2026
Event 12/31/2025
|
||
|
Orbimed Advisors LLC
13G/A
|
0% |
8/14/2026
Event 6/30/2026
|
||
| Orbimed Advisors LLC | 0% | |||
| Orbimed Capital LLC | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 15.0 k | $4.62 k |
| 2026 Q2 | 58 | 11.8 M | $2.54 M |
| 2026 Q1 | 62 | 15.3 M | $8.18 M |
| 2025 Q4 | 65 | 13.8 M | $8.84 M |
| 2025 Q3 | 67 | 23.9 M | $83.7 M |
| 2025 Q2 | 56 | 15.5 M | $30.3 M |
| 2025 Q1 | 52 | 15.9 M | $39.0 M |
| 2024 Q4 | 62 | 15.5 M | $44.9 M |
| 2024 Q3 | 55 | 15.3 M | $45.3 M |
| 2024 Q2 | 50 | 15.2 M | $52.3 M |
| 2024 Q1 | 49 | 14.7 M | $76.9 M |
| 2023 Q4 | 55 | 16.9 M | $86.5 M |
| 2023 Q3 | 41 | 3.00 M | $15.7 M |
| 2023 Q2 | 34 | 967 k | $1.81 M |